Facebook
Twitter
LinkedIn
ForwardCotreatment of Hairy Cell Leukemia and Melanoma With the BRAF Inhibitor Dabrafenib
The activating BRAF mutation p.V600E has been identified in many cancers, including colon and lung adenocarcinoma, papillary thyroid cancer, malignant melanoma, and hairy cell leukemia (HCL). Malignant melanoma and HCL are of particular interest because of both the high proportion of cases harboring the mutation and the dramatic responses to BRAF inhibitor therapy reported in the literature. This report presents a patient with HCL and malignant melanoma with the BRAF V600E mutation, and discusses the successful treatment of both cancers with the BRAF inhibitor dabrafenib.
Target Audience
This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Explain the potential benefit of utilizing a single BRAF inhibitor to treat a patient with multiple BRAF-mutated malignancies
| James S. Blachly, MD Division of Hematology, Department of Internal Medicine The Ohio State University Columbus, Ohio | Gerard Lozanski, MD Department of Pathology The Ohio State University Columbus, Ohio |
| David M. Lucas, PhD Division of Hematology, Department of Internal Medicine The Ohio State University Columbus, Ohio | Michael R. Grever, MD Division of Hematology, Department of Internal Medicine The Ohio State University Columbus, Ohio |
| Kari Kendra, MD, PhD Division of Oncology The Ohio State University Columbus, Ohio | Leslie A. Andritsos, MD Division of Hematology, Department of Internal Medicine The Ohio State University Columbus, Ohio |
Available Credit
- 0.50 Participation
- 0.50 Nurse
- 0.50 Physician
Price
Required Hardware/software
To access this activity, users will need:
- A device with an Internet connection
- Adobe Reader or other PDF reader software for article and certificate viewing/printing